RxDoctor Payments Data

Katherine Santosa, MD

Plastic and Reconstructive Surgery · Atlanta, GANPI 1437410511

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.2%), grants and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by AbbVie at 33.2% of the total. Reporting peaked in 2024 at $30,944 and has fallen 83.4% since, to $5,123 in 2025. Among plastic and reconstructive surgery clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$64,775in general payments, 2019–2025

Across 287 payments — averaging $225.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$21K
  • Acera Surgical, Inc.$21K
  • Biosense Webster, Inc.$15K
  • Mentor Worldwide LLC$4K
  • Motiva USA, LLC$1K
  • Integra Lifesciences Corporation$600
  • plus $2K from 15 others
$2,507in research payments, 2019–2025

Across 1 payment — averaging $2506.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acera Surgical, Inc.$3K

What the payments were for

  • Consulting fees$27,31242%
  • Speaking & faculty fees$8361%
  • Grants$15,00023%
  • Travel & lodging$7,28211%
  • Food & beverage$13,88621%
  • Education$470%
  • Gifts$870%
  • Other$3261%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,775 in reported general payments places this provider in the 90th percentile of 83 plastic and reconstructive surgery providers in Georgia.

See all plastic and reconstructive surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$21,001
Medicare patients
25
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate40$268
Ondansetron OdtOndansetron33$227
Oxycodone Hcl31$125

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →